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Abstract

CLINICAL STUDIES CONDUCTED OVER THE TOTAL PRODUCT LIFE CYCLE OF
HIGH-RISK THERAPEUTIC MEDICAL DEVICES RECEIVING US FOOD AND DRUG
ADMINISTRATION PREMARKET APPROVAL IN 2010 AND 2011.

Vinay K. Rathi, Harlan M. Krumholz, Frederick A. Masoudi, and Joseph S. Ross.

Center for Outcomes Research and Evaluation, Yale University School of Medicine and
Yale-New Haven Hospital, New Haven, Connecticut.

The US Food and Drug Administration (FDA) approves high-risk medical devices,
those that support or sustain human life or present potential unreasonable risk to patients, via
the Premarket Approval (PMA) pathway. In recent years, the FDA has begun shifting
premarket evidentiary requirements to the postmarket period as part of a broader effort to
continually evaluate device safety and effectiveness throughout the total product life cycle.
We therefore sought to characterize the clinical evidence generated for high-risk therapeutic
devices over the total product life cycle. In October 2014, we identified all clinical studies of
high-risk therapeutic devices receiving initial market approval via the PMA pathway in 2010
and 2011 through ClinicalTrials.gov and publicly available FDA documents. Studies were
characterized by type (pivotal, studies that served as the basis of FDA approval; FDArequired postapproval studies [PAS]; or manufacturer/investigator-initiated); premarket or
postmarket; status (completed, ongoing, or terminated/unknown); and design features,

including enrollment, comparator, and longest duration of primary effectiveness end point
follow-up. We identified 286 clinical studies of the 28 high-risk therapeutic devices which
received initial marketing approval via the PMA pathway in 2010 and 2011: 82 (28.7%)
premarket and 204 (71.3%) postmarket, among which there were 52 (18.2%) nonpivotal
premarket studies, 30 (10.5%) pivotal premarket studies, 33 (11.5%) FDA-required PAS, and
171 (59.8%) manufacturer/investigator-initiated postmarket studies. Six of 33 (18.2%) PAS
and 20 of 171 (11.7%) manufacturer/investigator-initiated postmarket studies were reported
as completed. No postmarket studies were identified for 5 (17.9%) devices; 3 or fewer were
identified for 13 (46.4%) devices overall. Median enrollment was 65 patients (interquartile
range [IQR], 25-111), 241 patients (IQR, 147-415), 222 patients (IQR, 119-640), and 250
patients (IQR, 60-800) for nonpivotal premarket, pivotal, FDA-required PAS, and
manufacturer/investigator-initiated postmarket studies, respectively. Approximately half of
all studies used no comparator (pivotal: 13/30 [43.3%]; completed postmarket: 16/26
[61.5%]; ongoing postmarket: 70/153 [45.8%]). Median duration of primary effectiveness
end point follow-up was 3.0 months (IQR, 3.0-12.0), 9.0 months (IQR, 0.3-12.0), and 12.0
months (IQR, 7.0-24.0) for pivotal, completed postmarket, and ongoing postmarket studies,
respectively. In conclusion, among high-risk therapeutic devices approved via the FDA PMA
pathway, total product life cycle evidence generation varied in both the number and quality
of premarket and postmarket studies, with approximately 13% of initiated postmarket studies
completed between 3 and 5 years after FDA approval.
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Introduction
Medical Device Risk Classification & Regulatory Pathways
The United States Food and Drug Administration (FDA) primarily regulates medical
devices through 1 of 3 pathways – the 510(k) Premarket Notification (510[k]), Humanitarian
Device Exemption (HDE), and Premarket Approval (PMA) pathways.1-3 The pathway
through which each device is regulated depends on the risk associated with use, the intended
patient population, and the presence of similar previously marketed devices. First established
under the 1976 Medical Device Amendments Act, the FDA risk classification system for
devices categorizes products into 1 of 3 tiers based on the level of regulatory control
necessary to assure device safety and effectiveness (Class I – low risk, Class II – moderate
risk, and Class III – high-risk; Table 1).4 Roughly two-thirds of all devices regulated by the
FDA are classified as low-risk; these devices (e.g., dental floss and walking canes) are
subject to general regulatory controls such as good manufacturing practices and largely
exempt from FDA premarket review.5 Approximately 30% of devices are classified as
moderate-risk; these devices (e.g., electrocardiographs and tympanostomy tubes) are
regulated via the 510(k) pathway and require both general and special (e.g., performance
standards) regulatory controls for marketing. High-risk devices – those that support or sustain
human life, are of substantial importance in preventing illness, or present potential,
unreasonable risk to patients – comprise a small fraction of all devices. These devices (e.g.,
coronary stents and hip implants) are regulated either via the PMA or HDE pathways, the
latter of which is reserved for devices used in the diagnosis or treatment of uncommon
illnesses affecting fewer than 4,000 patients in the United States each year.
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Table 1. FDA Risk Classification System for Medical Devices
Device

Risk

Regulatory

FDA Review

Premarket

Class

Classification

Controlsa

Pathwayb

Evidence

Examples

Requirements
Class I

Low-risk

General Controls

None

None

Walking cane and

(e.g., good

nasal oxygen

manufacturing

cannula

practices and
manufacturer
registration with
FDA)
Class II

Moderate-risk

General Controls

510 (k)

Substantial

Electrocardiograph

and Special

Premarket

equivalence to

and diagnostic

Controls (e.g.,

Notification

predicate 510 (k)

intravascular

performance

device; rarely

catheter

standards and

requires clinical

special labeling

evidence

requirements)
Class III

High-risk

General Controls

Premarket

Clinical evidence

Replacement heart

and Premarket

Approval or

providing reasonable

valve and

Approval or

Humanitarian

assurance of device

implantable

Humanitarian

Device

safety and

cardiac

Device Exemption

Exemption

effectiveness

defibrillator

(Premarket

3
Approval) or safety
and probable benefit
(Humanitarian
Device Exemption)
a

Exceptions include select Class I devices exempt from good manufacturing practices and Class III devices
subject to Special Controls
b
Exceptions include select Class I and Class III devices reviewed via the 510 (k) pathway

Premarket Clinical Evidence Requirements & Generation
Device manufacturers must satisfy FDA premarket evidence requirements prior to
marketing moderate- and high-risk devices. To obtain marketing clearance for a new device
via the 510(k) pathway, manufacturers must demonstrate that the device is “substantially
equivalent” in materials, purpose, and mechanism of action to a previously marketed
“predicate” device (or components thereof);3,6 fewer than 10% of 510(k) submissions to the
FDA require clinical evidence for clearance.3 In recent years, the 510(k) pathway has come
under increased scrutiny in the wake of high-profile device recalls (e.g., the Depuy ASR
metal-on-metal hip implant, which was withdrawn from the market in 2010 after the National
Joint Registry for England and Wales reported a 5-year revision rate of 13%);7-9 in 2011, the
Institute of Medicine issued a report recommending that the 510(k) pathway be replaced by
an entirely new regulatory framework for moderate-risk devices.5,10 Criticism of the 510(k)
pathway centers around 5 major issues. First, certain high-risk devices are still permitted to
enter the market via the less stringent 510(k) pathway as a result of temporary exemptions
dating back to the 1976 Medical Device Amendments Act.11-14 Second, manufacturers may
obtain marketing clearance on the basis of substantial equivalence to unsafe predicates,
including permanently recalled devices.15 Third, manufacturers may claim unproven new
devices to be substantially equivalent to predicates with different technological
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characteristics and indications for use.11,16,17 Fourth, manufacturers may market poorly
understood technologies through the process of “predicate creep,” whereby multiple cycles of
substantial equivalence determinations result in a new device that is quite dissimilar from the
original predicate.15,16 Fifth, the FDA has permitted manufacturers to market chimeric new
devices on the basis of substantial equivalence to the individual characteristics of several
distinctly different predicates (i.e., “split” predicates).7 In response to these criticisms, the
FDA has committed to transitioning all high-risk devices away from the 510(k) pathway,11,12
improving the quality of publicly available summaries of scientific data supporting each
device,18 and adopting less permissive standards of substantial equivalence (e.g., prohibiting
split predicates).3
In contrast to the 510(k) pathway, the PMA pathway is intended to regulate high-risk
devices and requires premarket clinical evidence providing reasonable assurance of device
safety and effectiveness as a condition of approval;1 in addition, manufacturers must submit
supplemental PMA applications prior to implementing any post-approval changes affecting
device safety or effectiveness (e.g., design modifications or labeling changes expanding
indications for use).19 By statute, the FDA may only require manufacturers to generate the
“least burdensome” clinical data necessary to establish device safety and effectiveness.20
Though these data requirements are more stringent than those of European regulators,21,22
recent studies have criticized the strength of clinical evidence supporting FDA approval of
high-risk devices.23-25 Whereas most novel pharmaceuticals are approved on the basis of 2
large double-blind randomized controlled trials demonstrating independent evidence of
efficacy,26 FDA premarket evaluation of device safety and effectiveness typically focuses on
a single clinical study without blinding, comparators, or clinical (i.e., non-surrogate) primary
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endpoints.23,24,27 In addition, the external validity of these studies is often limited by small
enrollment numbers and inadequate representation of important subpopulations, including
women, racial minorities, and children.24,25
Calls for more robust premarket clinical evidence have grown louder following recent
device failures, such as fractures (Medtronic Sprint Fidelis) and insulation breakdowns (St.
Jude Riata) of widely-used cardioverter-defibrillator leads.28,29 Unlike pharmaceuticals, many
high-risk devices are implantable and cannot simply be discontinued when concerns arise,
leaving patients and physicians to weigh the risks of re-operation against leaving potentially
harmful foreign bodies in place.27,30 Furthermore, high-risk devices often undergo extensive
postmarket changes via supplemental PMA applications,31-33 which are typically approved
without supporting clinical evidence19 and may be subject to less stringent review than
intended by the FDA (e.g., labeling changes expanding indications for use approved via
review tracks requiring only pre-clinical data).32 In a recent study, implantable cardiac
electronic devices were found to have accumulated nearly 30 labeling or design changes over
their market life, with approximately one-fifth of major design changes supported by new
clinical data.33 These incremental changes may nonetheless pose unanticipated danger to
patients (e.g., otogenic meningitis caused by the addition of an electrode positioner to
Advanced Bionics CII cochlear implant),34 reduce therapeutic benefit (e.g., spontaneous
shutdown of the best-selling and recently recalled Cochlear Nucleus CI500),35 and ultimately
lead devices used in practice to differ substantially from those originally described in
published studies.31
Premarket evidentiary standards are lower for high-risk devices approved via the
HDE pathway, which does not require reasonable assurance of device effectiveness for
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marketing; instead, manufacturers must provide clinical evidence of safety and "probable
benefit" to obtain FDA approval.2 Prior work has accordingly found HDE approvals to be
supported by less rigorous clinical studies,36 leading patients to be implanted with devices
that were subsequently proven dangerous (e.g. the Wingspan neurovascular stent, which was
found to cause an increased risk of stroke and death in implanted patients).37 Nonetheless, the
FDA and Congress have recently proposed regulatory reforms that would lower premarket
evidence requirements for high-risk devices in an effort to expedite patient access to new
therapies and promote technological innovation.38,39
Postmarket Clinical Evidence Requirements & Generation
To complement premarket understanding of safety and effectiveness, the FDA has
become increasingly committed to devices throughout their “total product life cycle,”40 an
approach that involves ongoing study and reevaluation for as long as devices remain in use.41
As part of this approach, the FDA conducts both passive and active postmarket data
collection following device approval. The FDA conducts passive data collection through 3
distinct reporting programs, known as Mandatory Medical Device Reporting, MedWatch,
and the Medical Product Safety Network.42 Mandatory Medical Device Reporting requires
manufacturers, importers, and user facilities (i.e., hospitals, nursing homes, and outpatient
treatment and diagnostic centers) to report all deaths and serious adverse events for which a
device is suspected or known to have caused or contributed to patient harm.43 MedWatch is a
voluntary reporting program enabling consumers and healthcare professionals to alert the
FDA about all manner of safety issues, ranging from product quality problems and potential
harms to serious adverse events and death.44 The Medical Product Safety Network consists of
approximately 250 clinical sites, which have partnered with the FDA to identify safety
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concerns beyond the scope of Mandatory Medical Device Reporting (e.g., product use errors
and close calls).45
While these passive surveillance measures may help detect safety signals and assess
real-world device performance (e.g., hydrocephalus shunt valve failures due to rough
handling),46 their utility is greatly limited by the variable quality and inadequate number of
reports,47-49 which are often delayed in their submission by manufacturers and review by the
FDA (e.g., deaths caused by vagus nerve stimulators reported several years later).47,48 These
unstandardized reports often lack critical information necessary to identify devices,
understand adverse events, and exclude unrelated factors (e.g., procedural errors) as the cause
of harm.48 This critical information is altogether unavailable for reports never submitted as a
result of poor end-user engagement; only 6% of adverse event reports originate from
consumers and healthcare professionals48 who may be impeded by fear of litigation, failure to
connect devices to outcomes, and insufficient knowledge or support to fulfill reporting
obligations.47,48,50 The pervasive problem of underreporting is compounded by the fact that
manufacturers determine whether adverse events are linked to devices and need not report
unrelated incidents, which may incentivize mischaracterization of negative outcomes.47,48,51
Both underreporting and lack of information on the number of devices in use prevent
calculation of product-specific adverse event rates through passive surveillance, thereby
decreasing the strength of safety signals relative to noise and precluding direct comparison
between devices.48,49
In addition to monitoring passively collected reports, the FDA can actively address
clinical questions by requiring manufacturers to complete postmarket studies. The FDA is
authorized to order 2 types of postmarket studies, known as 522 Postmarket Surveillance
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Studies and Post-Approval Studies (PAS).52,53 522 Postmarket Surveillance Studies (522
studies) may be ordered at any point during the market life of a device, and are most often
initiated in response to safety concerns emerging in the course of real-world clinical practice
(e.g., infection transmission via reprocessed duodenoscopes).54 The FDA may order 522
studies up to 3 years in duration for both 510(k) and PMA-regulated devices, provided that
the device meets any of the following 4 criteria: (1) failure would be reasonably likely to
have adverse health consequences, (2) expected to have significant use in pediatric
populations, (3) intended to be implanted in the body for more than 1 year, or (4) intended to
be a life-sustaining or life-supporting device operated outside a user facility.55 In practice,
nearly 95% these studies have examined devices cleared via the 510(k) pathway (i.e., on the
basis of substantial equivalence), with more than three-quarters of these studies ordered for
metal-on-metal hip implants (cited above) and surgical mesh used in urogynecological
procedures (linked to adverse events such as dyspareunia and vaginal erosion and pain).56,57
Although the FDA has ordered roughly 400 postmarket surveillance studies to date,56 there
are concerns that these studies may have limited potential to inform regulatory and clinical
decision making as a result of delays by manufacturers avoiding unfavorable findings, lack of
harmonization to allow cross-product comparison, and inadequate follow-up to assess longterm outcomes.58
In contrast to 522 studies, the FDA may order PAS as a condition of approval for
devices regulated via the PMA (including supplemental applications) and HDE pathways.53
These studies are not subject to statutory limits on duration and typically designed to
complement premarket understanding of device safety and effectiveness with information
unavailable at the time of approval, such as evidence on long-term outcomes, expanded
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indications for use, and subgroup safety.56 These FDA-required studies serve as important
opportunities to assess device performance, and approximately half of PMA and HDE
devices approved since 1995 have been subject to PAS,59 three quarters of which involved
prospective clinical data collection (as opposed to laboratory or retrospective studies).56
However, PAS may often be small,60 delayed,37,60 or not generalizable to real-world
populations of use (including women and children).25,59 Moreover, only one-quarter of PAS
required by the FDA between 2005 and 2011 were completed.60 Nonetheless, PAS may have
significant implications for clinical practice, as study findings have prompted manufacturers
to remove unsafe devices from the market and update device labeling with critical
information (e.g., no dose-response for a depression treatment), though the effect of such
labeling changes on treatment decisions is unknown.60
Beyond FDA-required postmarket studies, complementary sources of evidence may
be generated through studies initiated by manufacturers or independent investigators. A
recent survey suggests that manufacturers may primarily conduct postmarket clinical studies
to comply with regulatory requirements.61 Alternatively, these companies may also choose to
invest in postmarket studies as a means to broaden applications of use and clinical acceptance
of a product.62 As the FDA adopts more flexible premarket evidence standards to expedite
patient access to new technologies,38,63,64 the information generated from both FDA-required
and manufacturer/investigator-initiated postmarket studies will become increasingly
important in guiding regulatory and clinical decisions.
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Statement of Purpose
Our objective was to characterize the clinical studies of high-risk therapeutic devices
initially approved via the FDA PMA pathway between 2010 and 2011 to better understand
the amount and quality of evidence generated over the total product life cycle. Prior to
conducting this study, we put forth the following specific hypotheses:

1. The FDA will have approved virtually all high-risk therapeutic devices receiving
initial Premarket Approval in 2010 and 2011 on the basis of a single pivotal clinical
study; additional premarket clinical evidence generated through feasibility studies of
these devices will be of limited strength due to small enrollment numbers.
2. The number of postmarket studies per device will vary widely; little postmarket
evidence will have been generated for a significant proportion of devices.
3. Manufacturers and independent investigators will initiate a significant proportion of
postmarket studies without FDA requirement; many of these studies will assess
devices in clinical contexts beyond those specified by FDA-approved indications.
4. Postmarket device studies will be of higher quality compared to premarket studies,
particularly with respect to enrollment number, comparator, and duration of primary
endpoint follow-up.
The specific aim of the thesis was twofold: (1) to promote critical evaluation of the clinical
evidence available to inform medical decision-making about high-risk medical devices by
patients and physicians and (2) to inform ongoing legislative and regulatory efforts seeking
to balance pre- and postmarket evidentiary requirements for high-risk medical devices and
develop robust methods of postmarket surveillance.
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Methods

Sample Construction
We constructed a sample of high-risk therapeutic devices initially receiving US
marketing approval via the FDA PMA pathway between January 1, 2010 and December 31,
2011 using the publicly accessible PMA database (Figure 1).65 We selected this sample
period in order to ensure that the majority of relevant trials were registered on
ClinicalTrials.gov – an online public clinical trials registry maintained by the National
Library of Medicine – in compliance with the 2007 FDA Amendments Act.66 We used
information on device type listed within the FDA database to exclude all nontherapeutic (i.e.,
diagnostic) devices,67 including detection kits, molecular assays, and imaging machines.
Based on information within the publicly available FDA Summary of Safety and
Effectiveness Data (SSED, hereafter referred to as the FDA Summary) linked to each
original PMA application,68 we further excluded therapeutic devices that were previously
marketed in the United States for another indication.
Device Characteristics
Using information within the PMA database, we classified each device in our sample
by the following characteristics: approval year, medical specialty area,67 review type
(normal/expedited), implantable designation (yes/no), and life-saving designation (yes/no).
We also characterized their recall history by searching the FDA’s online Medical Device
Recalls Database using PMA application numbers and recording the highest recall class for
each affected device (Class I-III).69
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Identification of Clinical Studies
We primarily identified clinical studies using ClinicalTrials.gov (Figure 2); with the
exception of small feasibility studies, the 2007 FDA Amendments Act required that all
device studies ongoing as of December 2007 be registered on ClinicalTrials.gov.66 For each
device in our cohort, we initially searched ClinicalTrials.gov for the device trade name
specified at the time of PMA application, any previously marketed trade names appearing in
the FDA Summary, and any newly marketed trade names appearing in the PMA database.
We included all resulting studies describing use of the device under these trade names,
excluding duplicates. Using the FDA Summary for each device, we then searched for any
trade names of its component devices as applicable. If the component was originally
approved as part of the PMA application, we included all newly identified studies describing
its use. If the component was not approved as part of the PMA application, we included any
newly identified studies describing its use as adjunctive to a comparable device that we could
not exclude as being the device of interest within our sample.
After searching for clinical studies of interest based on trade names, we then screened
further using combinations of manufacturer names and device descriptors as our search
terms. We first used information provided in the FDA Summary, the FDA website,70,71 and
manufacturer website to determine relevant device descriptors and abbreviations thereof for
each device (e.g., “bronchial radiofrequency” and “bronchial RF”), leveraging descriptors in
the generic technology name to differentiate our device of interest within the manufacturer’s
product line when necessary (e.g., “everolimus platinum stent” as opposed to “everolimus
stent” for Boston Scientific). We also searched the PMA database to identify all
manufacturers listed as applicants for each device in order to account for manufacturer
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mergers, acquisitions, and rebranding. For each device, we then searched ClinicalTrials.gov
for combinations of manufacturer name(s) and device descriptors. We included newly
identified resulting studies that mentioned relevant combinations of manufacturer name(s)
and device descriptors, provided that the study examined a technologically equivalent,
unnamed device that was both attributable to the correct manufacturer by study description or
sponsorship and conducted in a setting consistent with the marketing history outlined in the
FDA Summary. For devices produced by smaller manufacturers or with device descriptors
either highly specific in name or unique to a single manufacturer, we additionally searched
ClinicalTrials.gov for these manufacturer names and device descriptors alone. We included
newly identified studies resulting from these searches that described use of a comparable
device that we could not exclude as being the device of interest within our sample.
All searches were performed by VKR in October 2014. The principal investigator
(J.S.R.) reviewed all potentially relevant studies derived from this multi-step search
algorithm along with another investigator (V.K.R.) to determine appropriateness for
inclusion. We excluded studies with an enrollment status of “Not yet recruiting,”
“Suspended,” or “Withdrawn.” If an identified study compared two or more devices in our
sample, the study was counted once for each device.
Following our search of ClinicalTrials.gov, we then reviewed all feasibility and
pivotal studies described in FDA Summaries and PAS listed within the FDA PAS database;72
no 522 postmarket surveillance studies were ordered for devices in our sample.55 Pivotal
studies are those which serve as the primary basis for the FDA’s premarket evaluation of
device safety and effectiveness.73 Studies described solely within FDA documents were
included, even if not registered on ClinicalTrials.gov (Figure 2). For devices with sub-studies
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conducted in support of the PMA application, we considered each named sub-study with
FDA-required follow-up of the premarket cohort as a separate PAS.
Clinical Study Features
For all identified studies, we abstracted the following information from
ClinicalTrials.gov and/or FDA documents (Box 1): enrollment number, study status
(completed, ongoing, terminated/unknown), primary completion date (i.e., final data
collection for primary outcomes), and study type (pivotal study, FDA-required PAS, or
manufacturer/investigator-initiated study).
Box 1. Coding of Premarket & Postmarket Clinical Study Enrollment, Status, and Type
Enrollment: Study enrollment size was recorded as specified in the “Enrollment” field on
ClinicalTrials.gov or described in FDA approval letters mandating post-approval studies.
Study enrollment size for pivotal studies identified through FDA Summaries was recorded as
the number of randomized patients. For feasibility studies identified through FDA
Summaries, the number of patients receiving the study intervention was recorded as the
enrollment size.
Study status: For studies identified through ClinicalTrials.gov, study status was recorded as
most recently specified on the study page; studies listed as “Completed” were categorized as
completed, studies listed as “Recruiting,” “Enrolling by invitation,” or “Active, not
enrolling” were categorized as ongoing, and studies listed as “Terminated” or “Unknown”
were categorized as terminated/unknown. We considered all pivotal and feasibility studies
identified through FDA Summaries to be completed. We determined the study status of
FDA-required post-approval studies using the “Study Progress” field within the FDA PostApproval Studies database; studies were categorized as “Ongoing” if study progress was
reported as “Progress Adequate” or “Progress Inadequate,” “Unknown” if progress was
reported as “Study Pending,” and “Completed” if reported as such.
Primary completion date: For studies identified through ClinicalTrials.gov, primary
completion date was recorded as specified in the “(Estimated) Primary Completion Date”
field. In rare instances, no primary completion date was reported on ClinicalTrials.gov, and
we used information reported in the “Completion Date” field instead. If neither field was
populated, we estimated the primary completion date by adding the duration of longest
follow-up for the primary outcome measure to the date of last verification by the study
sponsor. For pivotal studies identified through FDA Summaries, we used the date of last data
collection as reported. For feasibility studies identified through FDA Summaries, we
performed a search of the literature to identify the completion date of the study as reported or
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estimate the primary completion date by adding the duration of longest follow-up to the date
of final patient enrollment. In rare instances, we were unable to locate a published report of
the feasibility study within the literature, and instead used a search of the Web to identify the
dates of news items reporting on the results of these studies. Studies with a primary
completion date prior to initial FDA marketing approval were categorized as premarket; all
other studies were categorized as postmarket.
Study type: Studies identified through ClinicalTrials.gov were determined to be pivotal or
post-approval studies if described as such within the “Official Title,” “Brief Description,” or
“Detailed Description” fields. We further identified pivotal and post-approval studies among
those identified through ClinicalTrials.gov by comparing reported enrollment size, setting,
and design features to study descriptions provided within FDA resources. All other studies
were considered to be manufacturer/investigator-initiated.
We then abstracted additional information on study features for all pivotal premarket,
completed postmarket, and ongoing postmarket studies; non-pivotal premarket and
terminated/unknown studies were excluded from further analysis because the information
available was often insufficient for characterization. We collected the following additional
study features (Box 2): funder, centers, location, registry design, blinding, study groups,
comparator, and randomization.
Box 2. Coding of Pivotal Premarket & Completed/Ongoing Postmarket Clinical Study
Features
Funder: Coded as “Industry,” “Other,” or “Mixed” (i.e., both industry and outside funding
sources) based on ClinicalTrials.gov downloadable output. Pivotal and post-approval studies
identified through FDA resources were considered to be “Industry” funded.
Centers: Coded as “Single-center” or “Multi-center.” Studies explicitly described as singlecenter or with only one study center listed were considered to be “Single-center.” All other
studies were considered to be “Multi-center.”
Locations: Coded as “All US,” “Some US,” or “No US” based on the description and/or
listing of study center locations. All multi-center studies with at least one US location listed
were considered to be “Some US.” Studies with no stated location were considered to be
“Some US.”
Registry: Coded as “Registry” or “Non-registry.” A clinical study was considered to be a
“Registry” if the term “registry” was used explicitly either in the study name or description.
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Blinding: Coded as “Open label”, “Single-blind”, or “Double-blind.” Studies described as
being blinded to an objective outcomes assessor or without explicit mention of blinding were
considered to be “Double-blind.” Studies described as being blinded to either patient or
investigator without mention of the other were considered to be “Single-blind.”
Observational, single-group, and registry studies were considered to be “Open label.” All
other studies were classified as reported.
Study Groups: Coded as “Single-group” or “Multi-group.” Studies explicitly described as
single-group, with only one group listed, or in which all groups received the same treatment
were considered to be “Single-group.” All other studies were considered to be “Multi-group.”
Comparators: Coded as “None”, “Active comparator,” or “Placebo/Sham.” Clinical studies
with standard of care as the control group were considered to have an “Active Comparator.”
Single-group studies were considered to have “None.” All other studies were classified as
reported.
Randomization: Coded as “Randomized”, “Non-randomized”, or “N/A.” Single-group
studies were classified as “N/A” because randomization is not possible in such a design.
Studies not explicitly described as being randomized were considered to be “Nonrandomized.” All other studies were classified as reported.
Using clinical experience and judgment, members of the study team (V.K.R. and
J.S.R.) additionally determined whether the indications for device use in each ongoing and
completed postmarket study (both FDA-required PAS and manufacturer/investigatorinitiated studies) differed from the original FDA-approved indication as explicitly described
in the corresponding FDA Summary. This determination (original or different) was made
based on information within the postmarket study description and inclusion/exclusion
criteria, which outlined the conditions and population for which the device was used. If there
was insufficient information to make a determination, we categorized the indication as not
differing by default. Of note, we did not consider studies using the Edwards Sapien
transcatheter heart valve in high-risk surgical patients to have a differing indication; although
the device was originally cleared for the treatment of inoperable patients, the same pivotal
study was used as the basis for approval in treating high-risk surgical patients as well. All
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data pertaining to clinical study features was abstracted by VKR; all characterizations of
indications were confirmed by JSR, with conflicts resolved by consensus. Several
representative examples of differing and non-differing indications are provided with
supporting rationale (Box 3).
Box 3. Characterization of Indications for Device Use in Postmarket Studies
Indications Differing from Original FDA-Approved Indication
Different Example #1
Original FDA indication: “The Arctic Front Cardiac CryoAblation Catheter and
CryoConsole (Arctic Front® Cryocatheter System) are indicated for the treatment of drug
refractory recurrent symptomatic paroxysmal atrial fibrillation.”
ClinicalTrials.gov study description: “The purpose of this study is to evaluate the
effectiveness of Pulmonary Vein Isolation (PVI) performed with the Arctic Front™ Advance
Cardiac CryoAblation Catheter System as first-line therapy in comparison with
antiarrhythmic drugs (AAD) in patients with paroxysmal atrial fibrillation (AF).”
Supporting rationale: Cryoballoon ablation was originally FDA-approved for the indication
of treating drug-refractory patients, but here is studied as first-line treatment.
Different Example #2
Original FDA indication: “The Edwards SAPIEN Transcatheter Heart Valve (THV), model
9000TFX, sizes 23mm and 26mm, is indicated for transfemoral delivery in patients with
severe symptomatic native aortic valve stenosis who have been determined by a cardiac
surgeon to be inoperable for open aortic valve replacement and in whom existing comorbidities would not preclude the expected benefit from correction of the aortic stenosis.”
ClinicalTrials.gov study description: “The purpose of this registry is to retrospectively and
prospectively obtain clinical data in consecutively treated patients, in order to demonstrate
that the commercially available Edwards SAPIEN Valve with the RF3 delivery system is a
safe and effective treatment for patients with pulmonary regurgitation or stenosis.”
Supporting rationale: Study assesses artificial heart valve implantation in the pulmonic
position, whereas device is originally FDA-approved for the indication of implantation in the
aortic position.
Different Example #3
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Original FDA indication: “Belotero® Balance is indicated for injection into the mid-to-deep
dermis for correction of moderate- to-severe facial wrinkles and folds such as nasolabial
folds.”
ClinicalTrials.gov study description: “Inclusion criteria: (1) Active stage TO [thyroid
opthalmopathy] as determined by symptom onset of under 9 months AND (2) Upper eyelid
retraction of 1 mm or greater in one or both eyes AND (3) Complaints of either significant
ocular symptoms (despite appropriate use of ocular lubricants), or cosmetic deformity
associated with the eyelid retraction”
Supporting rationale: Study assesses dermal filler for treatment of thyroid eye disease,
whereas the filler is originally FDA-approved for the indication of treating facial wrinkles.
Different Example #4
Original FDA indication: “The PROMUS Element Plus Everolimus-Eluting Platinum
Chromium Coronary Stent System is indicated for improving luminal diameter in patients
with symptomatic heart disease due to de novo lesions in native coronary arteries >2.25 mm
to <4.00 mm in diameter in lesions <28 mm in - length.”
ClinicalTrials.gov study description: “Inclusion criteria: long lesion (lesion length >30mm
by visual estimation) or in stent restenosis of bare metal stent or everolimus-eluting stent.”
Supporting rationale: Study includes patients with stent restenosis and patients with lesion
length ≥ 28 mm, but the stent was originally FDA approved for the indication of treating
symptomatic heart disease caused by de novo lesions < 28 mm in length. Lesions 28-34 mm
in length were approved as an indication for treatment via supplemental pre-market
application based on clinical evidence supporting a different size of the stent.
Indications Consistent with Original FDA-Approved Indication
Original Example #1
Original FDA indication: “The Alair ® Bronchial Thermoplasty System is indicated for the
treatment of severe persistent asthma in patients 18 years and older whose asthma is not well
controlled with inhaled corticosteroids and long acting beta agonists.”
ClinicalTrials.gov study description: “Inclusion Criteria: (1) Patient with severe persistent
asthma uncontrolled found in stable [condition] for at least 3 weeks AND (2) Patient
receiving regular treatment with inhaled corticosteroids (beclomethason[e] > 1000 mcg or
equivalent) and LABA (salmeterol >= 100 mcg or equivalent) AND (3) AQLQ score < 6.25
AND (4) FEV1 >= 60% predicted AND (5) Patients not smoking for at least one year ”
Supporting rationale: Patients eligible for inclusion must have uncontrolled asthma despite
receiving inhaled corticosteroid and long acting beta agonist treatment.
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Original Example #2
Original FDA indication: “The CeramaxTM Ceramic Total Hip System is indicated for
noncemented use in skeletally mature individuals undergoing primary total hip replacement
surgery for rehabilitation of hips damaged as a result of noninflammatory degenerative joint
disease (NIDJD) or any of its composite diagnoses of osteoarthritis, avascular necrosis, and
post-traumatic arthritis.”
ClinicalTrials.gov study description: “Inclusion Criteria: (1) Post-operative clinical
evaluation judged successful using Harris Hip Scoring system (HHS > 90) AND (2) Body
weight less than 270 lbs AND (3) No evidence of post-operative hip subluxation or
dislocation AND (4) Do not walk with detectable limp AND (5) Be able to actively abduct
their operated hip against gravity without falling AND (6) Must be willing to sign Informed
Consent and Health Insurance Portability and Accountability (HIPAA) forms. Exclusion
Criteria: (1) Pregnant, lactating females or females not using reliable form of birth control
AND (2) Patients that do not meet study requirements AND (3) Patients unwilling to sign
Informed Consent or HIPAA forms”
Supporting rationale: Insufficient information is provided to determine the indications for
hip prosthesis implantation (i.e., inflammatory vs. non-inflammatory joint disease) among
study patients.
Original Example #3
Original FDA indication: “The Pipeline Embolization Device is indicated for the
endovascular treatment of adults (22 years of age or older) with large or giant wide-necked
intracranial aneurysms (IAs) in the internal carotid artery from the petrous to the superior
hypophyseal segments.”
ClinicalTrials.gov study description: “Inclusion Criteria: (1) Subjects who are age 22 or
higher AND (2) IA of at least 10 mm in maximum distension along the internal carotid artery
between the petrous and superior hypophyseal segments”
Supporting rationale: Inclusion criteria specify use of the device in the same patient
population (age 22 years or older) and disease state (large IA within specific anterior
circulation anatomical bounds) as the original FDA indication.
Original Example #4
Original FDA indication: “Gel-One ® is indicated for the treatment of pain in osteoarthritis
(OA) of the knee in patients who have failed to respond adequately to non-pharmacologic
therapy, non-steroidal anti-inflammatory drugs (NSAIDs) or analgesics, e.g.,
acetaminophen.”
ClinicalTrials.gov study description: “Inclusion Criteria: (1) Have knee pain AND (2) Grade
1 to 3 on the Kellgren-Lawrence grading scale [for radiographic evaluation of osteoarthritis].
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Exclusion Criteria: (1) BMI greater than 35 kg/m2 AND (2) Received an intra-articular
hyaluronic acid injection for the treatment of OA of the knee within 6 months prior to
screening AND (3) Had a joint replacement of the target knee”
Supporting rationale: Inclusion criteria specify device use for the indication of knee pain
secondary to osteoarthritis. Insufficient information is provided to definitively determine
whether the device is to be used as first- or second-line treatment (i.e., whether patients have
failed non-pharmacologic and pharmacologic therapies prior to enrollment).

Clinical Study Primary Effectiveness Endpoints
We identified and characterized all primary effectiveness endpoints assessed in
pivotal premarket, completed postmarket, and ongoing postmarket studies. Primary endpoints
of pivotal and postmarket studies identified through ClinicalTrials.gov were recorded as
reported in the “Current Primary Outcome Measures” field on each study page. Additionally,
we searched the FDA Summary for each pivotal study registered on ClinicalTrials.gov to
identify any additional primary endpoints discussed in the study description. We classified
endpoints describing adverse events or other sequelae related to previous treatment with the
study device (e.g., blood metal ion level measurement following metal-on-ceramic hip
implantation) as safety endpoints. We classified endpoints describing the state of the medical
condition for which the patient received treatment with the study device (e.g., number of
severe respiratory exacerbations observed in asthma patients undergoing bronchial
thermoplasty) as effectiveness endpoints. In the event that a composite endpoint described
elements of both, we classified the endpoint as an effectiveness endpoint. Mortality was
considered an effectiveness endpoint unless specifically designated otherwise; whenever an
endpoint was explicitly classified on ClinicalTrials.gov, we considered it to be as such.
For pivotal studies identified through FDA Summaries, we classified endpoints as
explicitly named. If only one primary endpoint was named for a pivotal study, we considered
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it to be an effectiveness endpoint. If no primary endpoint was explicitly named, we
designated the endpoints discussed within the “Effectiveness Endpoints” and “Safety
Endpoints” sections as primary endpoints; in these select instances, a maximum of 3
endpoints were named in per section. We considered the primary endpoints of PAS providing
follow-up of previously enrolled cohorts to be the same as the original study, unless
explicitly specified otherwise by information within the Post-Approval Studies database.
For each primary effectiveness endpoint, we recorded the duration of longest followup (using the pre-specified duration for ongoing studies). Primary effectiveness endpoints
were then classified as “clinical outcomes,” “clinical scales,” or “surrogate markers of
disease” based on an established framework and a recent Institute of Medicine report.26,74
“Clinical outcomes” measure patient survival or function (e.g., overall survival, 50-foot walk
test, or freedom from reoperation). “Clinical scales” represent rubrics for the quantification
of subjective patient-reported symptoms (e.g., Harris Hip Score, best-corrected visual acuity,
or New York Heart Association Functional Classification Status). “Surrogate markers of
disease” represent biomarkers expected to predict clinical status (e.g., aortic insufficiency as
measured by echocardiogram, maximum observed everolimus blood concentration, or
reduction in smooth muscle surface area as objectified on bronchial biopsies). Endpoints
classified as “Clinical outcomes” and “Clinical scales” were grouped together and classified
as “Clinical outcomes” for purposes of analysis. Composite endpoints with both clinical and
surrogate components were considered to be “Clinical outcomes.” All data pertaining to
primary endpoints was abstracted by VKR; all characterizations of endpoints were confirmed
by JSR, with conflicts resolved by consensus.
Statistical Analysis
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We used descriptive statistics to characterize our high-risk therapeutic device sample. We
calculated median enrollment numbers for non-pivotal premarket, pivotal premarket, FDArequired PAS, and manufacturer/investigator-initiated postmarket studies, and used the
Kruskal-Wallis test to assess for a difference between these 4 study types. We then used
descriptive statistics to characterize all other features of pivotal premarket, completed
postmarket, and ongoing postmarket clinical studies; FDA-required PAS and
manufacturer/investigator-initiated postmarket studies were categorized together to provide a
holistic perspective of completed and ongoing postmarket evidence generation. Analyses of
primary effectiveness endpoints were conducted at the endpoint-level because some studies
had multiple primary effectiveness endpoints and some studies had only safety endpoints.
We then used χ2 and Kruskal-Wallis tests as appropriate to examine for differences in
features and primary effectiveness endpoints between these 3 study types. Analyses were
performed using Microsoft Excel 2011 and JMP version 10.0 (SAS Institute Inc.). All
statistical tests were 2-tailed, and we used a type 1 error rate of 0.05 in testing enrollment
number. To account for multiple comparisons, we used type I error rates of 0.006 and 0.0125
in testing all other study features (9 comparisons) and endpoint characteristics (4
comparisons), respectively.
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Results
Study Sample
Between 2010 and 2011, the FDA granted initial marketing approval for 28 high-risk
therapeutic devices via the PMA pathway: 21 (75.0%) were implantable and 9 (32.1%) were
life-sustaining (Table 1). About half (n=15; 53.6%) were for cardiovascular conditions. Ten
(35.7%) were recalled at least once, with one (3.6%) undergoing a Class I recall (highestrisk: reasonable probability of serious health problems or death) and one (3.6%) voluntarily
withdrawn from market.
Table 2. High-Risk Therapeutic Devices Receiving Initial Marketing Approval via the FDA
Premarket Approval Pathway in 2010 and 2011
No. (%)
Approval Year
2010

12 (42.9)

2011

16 (57.1)

Medical Specialty Area
Anesthesiology

2 (7.1)

Cardiovascular
Coronary stent

3 (10.7)

Non-coronary stent

12 (42.9)

Ear, Nose, and Throat

2 (7.1)

General and Plastic Surgery

1 (3.6)

Neurology

2 (7.1)
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Ophthalmology

3 (10.7)

Orthopedics

3 (10.7)

Priority Review
Yes

6 (21.4)

No

22 (78.6)

ImplantableA
Yes

21 (75.0)

No

7 (25.0)

Life-SustainingA
Yes

9 (32.1)

No

19 (67.9)

Highest Recall ClassB
Class I

1 (3.6)

Class II

8 (28.6)

Class III

1 (3.6)

Withdrawn

1 (3.6)

No Recall

17 (60.7)

Notes: FDA=Food and Drug Administration.
A
Determined based on the product code given for each device.
B
The FDA classifies recalls into 3 categories based on the relative degree of health hazard
presented by the device being recalled: Class I – reasonable probability of serious adverse
health consequences or death; Class II – reasonable probability of temporary or medically
reversible adverse health consequences, or remote probability of serious adverse health
consequences or death; and Class III – low probability of adverse health consequences.
Premarket & Postmarket Clinical Study Enrollment, Status, and Type

25
We identified 286 clinical studies of these 28 high-risk therapeutic medical devices
(Figure 3): 52 (18.2%) non-pivotal premarket studies, 30 (10.5%) pivotal premarket studies,
33 (11.5%) FDA-required PAS, and 171 (59.8%) manufacturer/investigator-initiated
postmarket studies. A total of 44 (84.6%) non-pivotal premarket studies were reported as
completed, as were all 30 (100.0%) pivotal premarket studies (Table 2). In contrast, 6
(18.2%) FDA-required PAS and 20 (11.7%) manufacturer/investigator-initiated postmarket
studies were reported as completed, with 23 (69.7%) and 130 (76.0%) reported as ongoing,
respectively; 2 (6.1%) FDA-required PAS were pending.
The median number of non-pivotal premarket studies per device was 1 (Interquartile
Range [IQR], 0-2), and 26 (92.9%) devices received FDA approval on the basis of a single
pivotal premarket study. At least 1 PAS was required by the FDA for 19 (67.9%) devices;
nearly all (n=29; 87.9%) were ordered as a condition of approval for the original PMA
application, while the remainder (n=4; 12.1%) were ordered following market introduction as
a condition of approval for a supplemental PMA application. The median number of
manufacturer/investigator-initiated postmarket studies was 3 (IQR, 1-6). We were unable to
identify any postmarket studies (including completed, ongoing, or terminated/unknown
studies) for 5 (17.9%) devices; 3 or fewer studies were identified for 13 (46.4%) devices
overall.
Median enrollment was 65 (Interquartile Range [IQR], 25-111), 241 (IQR, 147-415),
222 (IQR, 119-640), and 250 (IQR, 60-800) patients for non-pivotal premarket, pivotal,
FDA-required PAS, and manufacturer/investigator-initiated postmarket studies, respectively.
Median enrollment was lower among completed FDA-required PAS and
manufacturer/investigator-initiated postmarket studies (202 [IQR, 126-694] and 100 [IQR,
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43-252], respectively) than among ongoing postmarket studies (300 [IQR, 120-1115] and
300 [IQR, 60-1011], respectively).
Although only 3 of 28 (10.7%) devices in our sample were coronary stents, 75 of 179
(41.8%) completed and ongoing postmarket studies (including FDA-required PAS) examined
these devices. Among these coronary stent studies, median enrollment was 572 patients
(IQR, 237-2000), whereas median enrollment was 135 patients (IQR, 50-326) for the 104
studies of all other devices. Focusing on the 10 devices in our sample that were recalled at
least once, 67 of 104 (64.4%) ‘non-coronary stent’ completed and ongoing postmarket
studies examined these devices; median study enrollment was 130 patients (IQR, 50-318) for
recalled devices, 165 patients (IQR, 40-346) for non-recalled devices.
Table 3. Number of and Enrollment in Clinical Studies Examining High-Risk Therapeutic
Devices Receiving Initial Marketing Approval via the FDA Premarket Approval Pathway in
2010 and 2011, by Study Status and Type
Manufacturer/
Non-Pivotal

Pivotal

FDA-Required
Investigator

Premarket

Premarket

Post-Approval
Postmarket

(n=52)

(n=30)

(n=33)
(n=171)

Overall, No. (%)

52 (18.2)

30 (10.5)

33 (11.5)

171 (59.8)

44 (84.6)

30 (100.0)

6 (18.2)

20 (11.7)

3 (6.8)

0 (0)

23 (69.7)

130 (76.0)

5 (11.4)

0 (0)

4 (12.1)

21 (12.3)

No. (%) by Study Status
Completed
Ongoing

Terminated/Unknown
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Median No. Studies
1 (0-2)

1 (1-1)

1 (0-2)

3 (1-6)

per Device (IQR)
Median No. Studies per Device (IQR) by Study Status
Completed

1 (0-2)

1 (1-1)

0 (0-0)

0 (0-1)

Ongoing

0 (0-0)

0 (0-0)

1 (0-1)

2 (0-5)

0 (0-0)

0 (0-0)

0 (0-0)

0 (0-1)

241 (147-

222 (119-

415)

640)

Terminated/Unknown
Median Enrollment
65 (25-111)
(IQR)

250 (60-800)

Median Enrollment (IQR) by Study Status
Completed

241 (147-

202 (126-

415)

694)

50 (21-114)

100 (43-252)
300 (120-

Ongoing

65 (60-291)

N/A

300 (60-1011)
1115)

78 (57-104)

N/A

136 (69-210)

156 (55-1150)

Terminated/Unknown
Notes: FDA=Food and Drug Administration; IQR=Interquartile Range.
Pivotal Premarket & Completed/Ongoing Postmarket Clinical Study Features
Study features were characterized for 209 studies: 30 (14.4%) pivotal premarket
studies, 26 (12.4%) completed postmarket studies, and 153 (73.2%) ongoing postmarket
studies (Figure 2). Whereas all pivotal studies were solely funded by industry (30 of 30
[100.0%)] and virtually all were multi-center (28 of 30 [93.3%]) and enrolled U.S. patients
(29 of 30 [96.7%]), fewer postmarket studies were supported by industry (completed: 17 of
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26 [65.4%]; ongoing: 91 of 153 [59.5%]), were multi-center (completed: 18 of 26 [69.2%],
ongoing: 92 of 153 [60.1%]), and enrolled U.S. patients (completed: 15 of 26 [57.7%],
ongoing: 63 of 153 [41.2%]) (p values ≤ 0.002; Table 3). Pivotal and postmarket study
design features were otherwise broadly similar, as approximately 10% were designated
registries, roughly three-quarters were unblinded, and nearly half were single-group and thus
had no comparator. Among multi-group studies, more than three-quarters used active
comparators and were randomized. Finally, nearly half of all postmarket studies (83 of 179
[46.4%]) explicitly described examining devices for different indications than those
originally approved by the FDA (completed: 9 of 26 [34.6%], ongoing: 74 of 153 [48.4%]).
Table 4. Characteristics of Clinical Studies Examining High-Risk Therapeutic Devices
Receiving Initial Marketing Approval via the FDA Premarket Approval Pathway in 2010 and
2011, by Study Status and Type
Clinical Study Characteristic

Study Type and Status
Pivotal

Completed

Ongoing

Premarket

Postmarket

Postmarket

(n = 30)

(n = 26)

(n = 153)

P value

Funder, No. (%)
Industry

< 0.001
30 (100.0)

16 (61.5)

57 (37.3)

Mixed

0 (0.0)

1 (3.8)

34 (22.2)

Other

0 (0.0)

9 (34.6)

62 (40.5)

Centers, No. (%)

0.002

Multi-center

28 (93.3)

18 (69.2)

92 (60.1)

Single-center

2 (6.7)

8 (30.8)

61 (39.9)
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Locations, No. (%)

< 0.001

All US

15 (50.0)

9 (34.6)

38 (24.8)

Some US

14 (46.7)

6 (23.1)

25 (16.3)

1 (3.3)

11 (42.3)

90 (58.8)

No US
Registry, No. (%)

0.75

No

28 (93.3)

23 (88.5)

136 (88.9)

Yes

2 (6.7)

3 (11.5)

17 (11.1)

Blinding, No. (%)

0.06

Double-blind

6 (20.0)

2 (7.7)

8 (5.2)

Single-blind

5 (16.7)

2 (7.7)

25 (16.3)

Open label

19 (63.3)

22 (84.6)

120 (78.4)

Study Groups, No. (%)

0.29

Multiple-groups

17 (56.7)

10 (38.5)

83 (54.2)

Single-group

13 (43.3)

16 (61.5)

70 (45.8)
0.01A

Comparator, No. (%)
Active comparator

13 (43.3)

9 (34.6)

80 (52.3)

Placebo/Sham

4 (13.3)

1 (3.8)

3 (2.0)

None

13 (43.3)

16 (61.5)

70 (45.8)
0.19A

Randomization, No. (%)
N/A (Single-group)
Non-randomized
Randomized
Indication, No. (%)

13 (43.3)

16 (61.5)

70 (45.8)

0 (0.0)

2 (7.7)

13 (8.5)

17 (56.7)

8 (30.8)

70 (45.8)
0.19 B
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Original

N/A

17 (65.4)

79 (51.6)

Different

N/A

9 (34.6)

74 (48.4)

Notes: FDA= Food and Drug Administration; IQR=Interquartile Range. P values represent
statistical comparisons across study type and status for each clinical study characteristic.
A
Excluding single-group studies.
B
Excluding pivotal studies.
Pivotal Premarket & Completed/Ongoing Postmarket Clinical Study Primary Effectiveness
Endpoints
We identified 226 primary effectiveness endpoints among these 209 studies: 44
(19.5%) endpoints among 30 pivotal studies, 27 (11.9%) endpoints among 26 completed
postmarket studies, and 155 (68.6%) endpoints among 153 ongoing postmarket studies
(Figure 2). Nearly 80% (35 of 44) of pivotal study endpoints were clinical outcomes, in
contrast to 57.1% of postmarket study endpoints (completed: 14 of 27 [51.9%], ongoing: 90
of 155 [58.1%]; p=0.02) (Table 4). Median duration of endpoint follow-up was 3.0 months
(IQR, 3.0-12.0) for pivotal studies, 9.0 months (IQR, 0.3-12.0) for completed postmarket
studies, and 12.0 months (IQR, 7.0-24.0) for ongoing postmarket studies (p=0.002).
However, we found no difference in median duration of endpoint follow-up for implantable
device studies (pivotal: 12.0 months [IQR, 4.0-12.0], completed postmarket: 10.5 months
[IQR, 0.3-21.0], ongoing postmarket: 12.0 months [IQR, 8.0-24.0]; p=0.07).
Table 5. Primary Effectiveness Endpoints of Clinical Studies Examining High-Risk
Therapeutic Devices Receiving Initial Marketing Approval via the FDA Premarket Approval
Pathway in 2010 and 2011, by Study Status and Type
Study Type and Status
Pivotal

Completed

Ongoing

Premarket

Postmarket

Postmarket

P value
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Endpoints

Endpoints

Endpoints

(n = 44)

(n = 27)

(n = 155)

Clinical Outcome

35 (79.5)

14 (51.9)

90 (58.1)

Surrogate Marker

9 (20.5)

13 (48.1)

65 (41.9)

3.0 (3.0 -

9.0 (0.3 -

12.0)

12.0)

1.5 (0.0 -

6.0 (0.0 -

12.0)

12.0)

12.0 (4.0 -

10.5 (0.3 -

12.0)

21.0)

Endpoint Type, No. (%)
0.02

Median Duration of
Longest Follow-Up
(months) (IQR)

Overall

Non-ImplantableA

ImplantableA

12.0 (7.0 - 24.0)

0.002

12.0 (6.0 - 24.0)

0.01

12.0 (8.0 - 24.0)

0.07

Notes: FDA=Food and Drug Administration; IQR=Interquartile Range. P values represent
statistical comparisons across study type and status for endpoint type and median duration of
longest follow-up.
A
Determined based on the product code given for each device.
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Discussion
Study Findings & Prior Literature
Our characterization of the clinical studies examining high-risk therapeutic medical
devices initially approved via the FDA PMA pathway between 2010 and 2011 demonstrates
that the amount and quality of evidence generated over the total product life cycle varies
widely. Some devices are currently being evaluated through ongoing studies that, if
completed, will provide evidence on clinical outcomes for large numbers of patients with
planned follow-up of a year or longer. However, most devices have been or will be evaluated
through only a few studies, which often focus on surrogate markers of disease in small
numbers of patients followed over short time periods of time, and study indications that
differ from the original FDA-approved indication.
Premarket clinical studies of high-risk therapeutic devices were limited in number
and quality. Nearly all devices were cleared on the basis of 2 studies: 1 non-pivotal and 1
pivotal study. Non-pivotal studies are typically conducted to assess device feasibility,
enrolling a limited number of patients to examine device performance and guide premarket
development (e.g., design modifications) and clinical use (e.g., anatomical restrictions).75
Non-pivotal studies may also include internationally-based studies initiated prior to FDA
approval; in our study, all incomplete non-pivotal premarket studies were internationallybased. In addition, to support market approval, the FDA requires at least one pivotal study
providing substantial evidence of device safety and effectiveness. We found that pivotal
studies generally enrolled fewer than 300 patients and were often designed without blinding,
comparators, or primary endpoint follow-up exceeding 1 year. Our results are consistent with
previous studies of premarket evidentiary standards focused on devices used for
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cardiovascular diseases, rare conditions, and patients who are children or have unmet medical
needs,24,25,36,63 with the exception of primary endpoint selection; whereas prior work found
the majority of primary endpoints in pivotal studies to be surrogate markers of disease,24,25
we identified nearly 80% as clinical outcomes for devices in our sample. Nonetheless, our
findings confirm that premarket studies provide limited data to address important clinical
questions that often arise after approval, including those related to long-term device
performance, new indications or iterations, and safety and effectiveness in real-world
populations.32,33,36,76
Prior studies have not examined total product life cycle evidence generation for highrisk therapeutic devices, instead focusing solely on the FDA PAS program or orthopedic
prostheses, which often receive market clearance via the 510(k) regulatory pathway intended
for moderate-risk devices.60,77 We found that postmarket studies, like premarket studies, were
often small, un-blinded, and without comparators. In addition, postmarket studies – including
those examining implantable devices – were also generally limited to 1 year of primary
endpoint follow-up, and nearly half focused on surrogate markers of disease. However,
approximately 13% of identified postmarket studies were completed between 3 and 5 years
after FDA approval; three-quarters of postmarket studies remained ongoing. Postmarket
evidence may be generated from ongoing observational studies and registries before
completing primary effectiveness endpoint follow-up, as well as afterwards from longer-term
follow-up of safety endpoints. However, the potential for this postmarket evidence to inform
practice remains unclear, even under the presumption that all ongoing studies will be
completed, given that clinicians often rapidly adopt new devices after market introduction31,78
and short-comings of the medical device literature related to selective publication and
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selective outcome reporting.79-81 Furthermore, it is unclear how this evidence will inform
regulatory decisions, if at all, such as whether to recall a product. Interestingly, completed
and ongoing postmarket studies examining recalled and non-recalled devices were similar in
size.
Clinical & Policy Implications
The FDA has adopted a total product life cycle approach to device evaluation with the
understanding that, “[a]t the time of device approval, certain safety and effectiveness
questions may not be fully resolved [...] because controlled clinical studies do not fully
represent the benefit-risk profile of a device when used in real-world clinical practice.”64
Although the FDA may not require a PAS for every newly approved device, the agency often
requires a postmarket study to complement premarket understanding of device safety and
effectiveness. However, by law, the FDA may only require the “least burdensome”
postmarket data necessary to address unresolved clinical questions about devices,38 limiting
its capacity to mandate additional studies for the purpose of generating evidence to inform
regulatory and clinical decision-making. Furthermore, the FDA has not imposed penalties
against manufacturers failing to comply with postmarket study requirements mandated
through its PAS program.60 Our findings of limited premarket evidence generation and few
FDA-required postmarket studies highlight the need for continued study, either through
manufacturer-initiated or investigator-initiated studies, to advance postmarket understanding
of device safety and effectiveness. Approximately 85% of the postmarket studies we
identified were not initiated in response to FDA requirements, and 40% were conducted
without manufacturer support. To ensure generation of additional robust, objective evidence
to inform the use of high-risk devices in clinical practice, government agencies may consider
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taking on a more principal role in supporting postmarket research, as they have done for
several commonly used pharmaceutical products. For instance, the Patient-Centered
Outcomes Research Institute – newly established under the 2010 Patient Protection and
Affordable Care Act – could further prioritize funding of large, pragmatic comparative
effectiveness studies designed to empower patients and physicians with real-world data on
high-risk devices and their therapeutic alternatives.82
The “right” number and “appropriate” design of premarket and postmarket studies for
high-risk therapeutic devices should vary based on expected benefit and risk, therapeutic
alternatives, and anticipated challenges of widespread use, including physician learning
curves and facility expertise. For any given device, conducting numerous large studies with
long periods of follow-up may not be a feasible or efficient use of resources. However,
pending legislative efforts will only further reduce premarket evidence requirements for
medical devices in order to expedite patient access to new technologies.83 Although the FDA
has begun developing postmarket safety surveillance methods, used primarily for
pharmaceuticals and biologics, that leverage routinely collected electronic health information
through a distributed data model under its Mini-Sentinel initiative,84 the validity of these
methods remains uncertain and this approach cannot be used for surveillance of medical
devices until there is widespread adoption of unique device identifiers.85 Moreover, safety
surveillance efforts have uncertain applications for generation of comparative effectiveness
evidence or insights into long-term effectiveness of medical devices. Postmarket assessments
of both medical device safety and effectiveness in real-world practice through clinical trials,
registries, and analysis of health systems data will continue to provide complimentary
evidence to guide regulatory and clinical decision-making. With this framework in mind, the
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FDA has actively engaged in efforts to strengthen our national network of device registries
and develop powerful accompanying analytical tools through the Medical Device
Epidemiology Network and High-Performance Integrated Visual Environment initiatives,86-88
though much work remains to realize the promise of big data in analyzing health outcomes
across disparate sources.
Limitations
Our study has several limitations that deserve consideration. First, we may not have
identified all clinical studies of devices in our sample despite the inclusive nature of our
search algorithm, and our findings may thus under-represent the clinical evidence generated.
This is more likely true of non-pivotal premarket clinical studies, as these could have taken
place prior to the ClinicalTrials.gov registration requirements that took effect in late 2007.
Nevertheless, all pivotal studies were identified, and these studies represent the most robust
evidence available during premarket evaluation. Conversely, by including all studies
registered on ClinicalTrials.gov, our study may over-represent the clinical evidence
generated, particularly in the postmarket period; approximately one-third of clinical trials
remain unpublished even years after study completion and only one-fifth of completed trials
registered on ClinicalTrials.gov report their results,89,90 such that the results of many studies
we identified may never be disseminated to inform clinical practice. Second, we cannot
account for postmarket studies not registered on ClinicalTrials.gov, such as chart reviews or
case-studies, though the strength of evidence derived from these studies is often limited. In
addition, internationally-based studies may also be less likely to be registered on
ClinicalTrials.gov, although more than half of the postmarket studies we identified were
conducted entirely outside of the U.S. Similarly, observational studies and patient registries
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of medical devices are required to be registered on ClinicalTrials.gov under FDAAA and
comprised nearly half of the postmarket studies we identified. However, non-product-specific
registries (i.e., disease registries) were unlikely to have been identified, and may importantly
contribute to device evaluation over the total product life cycle.7,91,92 Third, our analysis was
cross-sectional and our search was completed in October 2014, allowing between 3 and 5
years for studies to be initiated and completed after FDA approval. It is likely that there will
be additional clinical studies examining these devices, and some of the studies we identified
as ongoing will be completed or already have been completed. However, we expect that most
major postmarket clinical studies of devices are likely to be initiated within 5 years of
approval given their relatively short market life, and our findings therefore likely reflect the
best evidence available and anticipated to inform clinical practice. Finally, our study was
focused on evidence generated for high-risk therapeutic devices receiving PMA approval.
Our findings do not apply to devices receiving market clearance via the 510(k) or
Humanitarian Device Exemption regulatory pathways, which are used less frequently for
high-risk devices and subject to lower evidentiary standards, nor to diagnostic devices
receiving PMA approval; of note, the FDA will no longer allow manufacturers to obtain
marketing clearance for high-risk devices via the 510(k) pathway in the near future,11,12
further enhancing the generalizability of our findings.
Conclusions
Among high-risk therapeutic devices approved via the FDA PMA pathway between
2010 and 2011, total product life cycle evidence generation varied in both the number and
quality of premarket and postmarket studies, with approximately 13% of initiated postmarket
studies completed between 3 and 5 years after FDA approval.
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Figures, Titles, and Legends
Figure 1. Sample Construction of High-Risk Therapeutic Devices Receiving Initial
Marketing Approval via the FDA Premarket Approval Pathway in 2010 and 2011

28527!Premarket!Approvals!listed!in!database!

24463!approvals!excluded!
due!to!date!outside!sample!
period!(2010:2011)!

4064!Premarket!Approvals!between!2010:2011!

!4007!approvals!excluded!
due!to!supplemental!
applica>on!type!

57)original!Premarket!Approvals!between!
2010:2011!

!23!approvals!excluded!due!
to!diagnos>c!device!type!

34)original!Premarket!Approvals!for!
therapeu>c!devices!between!2010:2011!

!6!approvals!excluded!due!to!
previous!device!marke>ng!
history!within!United!States!

28!therapeu>c!devices!receiving!ini>al!
marke>ng!approval!in!United!States!via!
Premarket!Approval!pathway!in!2010:2011!

Legend: Abbreviation: FDA, Food and Drug Administration.

47
Figure 2. Identification of Clinical Studies Examining High-Risk Therapeutic Devices
Receiving Initial Marketing Approval via the FDA Premarket Approval Pathway in 2010 and
2011
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286 total studies eligible for inclusion in device cohort total
product life cycle

Included

52 Non-Pivotal
Premarket Studies
-

Completed: 44
Ongoing: 3
Unknown: 5

30 Pivotal
Premarket Studies
-

Completed: 30
Ongoing: 0
Unknown: 0

33 FDA-Required
Post-Approval Studies
-

Completed: 6
Ongoing: 23
Unknown: 4

171 Non-FDA-Required
Postmarket Studies
-

Completed: 20
Ongoing: 130
Unknown: 21

209 studies with 226 primary endpoints characterized
-

Pivotal Premarket: 30 studies (44 endpoints)
Completed Postmarket: 26 studies (27 endpoints)
Ongoing Postmarket: 153 studies (155 endpoints)

Legend: “Unknown” includes studies of both terminated and unknown status. The 26
“Completed Postmarket” studies were comprised of 6 completed FDA-required PAS and 20
completed manufacturer/investigator-initiated postmarket studies (i.e., “Non-FDA-Required
Postmarket Studies”). Similarly, the 153 “Ongoing Postmarket” studies were comprised of
23 ongoing FDA-required PAS and 130 ongoing manufacturer/investigator-initiated
postmarket studies. Abbreviation: FDA, Food and Drug Administration.
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Figure 3. Evidence Generation for High-Risk Therapeutic Devices Receiving Initial
Marketing Approval via the FDA Premarket Approval Pathway in 2010 and 2011, including
premarket non-pivotal and pivotal studies and postmarket FDA-required Post-Approval
studies and manufacturer/investigator-initiated studies.

Legend: Each vertical bar represents the device Premarket Approval approval date, organized
from oldest (bottom) to newest (top). For each device, pre- and postmarket studies appear to
the left and right of the vertical bar, respectively. A single large registry study involving two
coronary stents in our cohort was excluded from the plot, as were the 3 premarket nonpivotal studies reported as “Ongoing.” Abbreviation: FDA, Food and Drug Administration.

